Teclistamab in patients with multiple myeloma and impaired renal function

被引：11
|
作者：
Joiner, Laura [1 ]
Bal, Susan [2 ]
Godby, Kelly N. [2 ]
Costa, Luciano J. [2 ,3 ]
机构：
[1] Univ Alabama Birmingham, Dept Pharm, Birmingham, AL USA
[2] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
[3] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, 1802 6th Ave South, Birmingham, AL 35294 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷 / 11期
关键词：
D O I：
10.1002/ajh.27063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E322 / E324
页数：3
相关论文
共 50 条
  • [1] Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function
    Bergner, Raoul
    Henrich, Dirk M.
    Hoffmann, Martin
    Honecker, Andrea
    Mikus, Gerd
    Nauth, Bettina
    Nagel, Dietmar
    Uppenkamp, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (08): : 942 - 950
  • [2] Improvement in renal function in patients with multiple myeloma and impaired renal function receiving novel agent induction therapies
    Li, Liang
    Hu, Shuai
    Zhu, Hao
    Wang, Yaning
    Ma, Lian
    Booth, Brian P.
    Rahman, Nam Atiqur
    Schwartz, Janice
    Blumenthal, Gideon
    Liu, Qi
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function
    Chen, Jin
    Liu, Hui
    Li, Lijuan
    Liu, Zhaoyun
    Song, Jia
    Wang, Guojin
    Wang, Huaquan
    Ruan, Erbao
    Ding, Kai
    Shao, Zonghong
    Fu, Rong
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (05)
  • [4] Bendamustine pharmacokinetics and safety are not afflicted by impaired renal function in patients with multiple myeloma.
    Preiss, R
    Teichert, J
    Poenisch, W
    Niederwieser, D
    Matthias, M
    Merkle, K
    BLOOD, 2003, 102 (11) : 381B - 382B
  • [5] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
    Lebreton, P.
    Lachenal, F.
    Bouillie, S.
    Pica, G. M.
    Aftisse, H.
    Pascal, L.
    Montes, L.
    Macro, M.
    Johnson, N.
    Harel, S.
    Fernandez, M.
    De Renzis, B.
    Lioure, B.
    Lazareth, A.
    Javelot, M.
    Louni, C.
    Huart, A.
    Perrot, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
  • [6] Teclistamab for the treatment of multiple myeloma
    Sester, Lilli Sophie
    Goldschmidt, Hartmut
    Nitschmann, Sirka
    INNERE MEDIZIN, 2023, 64 (02): : 214 - 216
  • [7] A STUDY OF RENAL FUNCTION IN PATIENTS WITH MULTIPLE MYELOMA
    ARMSTRONG, JB
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1950, 219 (05): : 488 - 493
  • [8] Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
    Jagannath, S
    Barlogie, B
    Berenson, JR
    Singhal, S
    Alexanian, R
    Srkalovic, G
    Orlowski, RZ
    Richardson, PG
    Anderson, J
    Nix, D
    Esseltine, DL
    Anderson, KC
    CANCER, 2005, 103 (06) : 1195 - 1200
  • [9] Use of Bortezomib in recurrent and refractory multiple myeloma and impaired renal function
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 233 - 233
  • [10] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
12345